Infinite longevity is coming for this generation of kids.

Infinite longevity is coming for this generation of kids. | Well, infinite longevity, too. Yeah. >> Exactly. And so, I mean, they can't be more optimistic about the future.

Watch events: Life Biosciences ER-100 Phase 1 first readout (likely late 2026/early 2027)

Well, infinite longevity, too. Yeah. >> Exactly. And so, I mean, they can't be more optimistic about the future.

Beneficiaries (19)

Adverse (4)

{
  "nia": false,
  "url": "https://www.youtube.com/watch?v=X94eBT-VZnc",
  "mode": "PROPHECY",
  "role": "Host",
  "context": "AI's going to like give us superpowers. We're going to take over the world.\" >> Well, infinite longevity, too. Yeah. >> Exactly. And so, I mean, they can't be more optimistic about the future.",
  "to_year": 2100,
  "verbatim": "Well, infinite longevity, too. Yeah. >> Exactly. And so, I mean, they can't be more optimistic about the future.",
  "conv_cues": "infinite longevity, too",
  "direction": "HAPPEN",
  "from_year": 2040,
  "timeframe": "future (within current kids' lifetimes)",
  "conv_level": "HIGH",
  "milestones": [
    {
      "kind": "prereq",
      "label": "Colossal gene editing efficiency has risen from 15% industry / 40% internal to 90% at hundreds of edits",
      "status": "hit",
      "weight": 0.5,
      "ordinal": -12,
      "source_id": "245_025",
      "expected_date": "2026-04-29",
      "observed_date": "2026-04-29"
    },
    {
      "kind": "prereq",
      "label": "Colossal has major announcements coming this year with a local government on productionizing cloning of endangered species",
      "status": "pending",
      "weight": 0.5,
      "ordinal": -11,
      "source_id": "245_014",
      "expected_date": "2026-05-30",
      "observed_date": null
    },
    {
      "kind": "prereq",
      "label": "Longevity VC market expected to grow from $8.5B in 2024 to $12-18B in 2026.",
      "status": "pending",
      "weight": 0.5,
      "ordinal": -10,
      "source_id": "235_027",
      "expected_date": "2026-08-14",
      "observed_date": null
    },
    {
      "kind": "llm_pre_event",
      "label": "Life Biosciences ER-100 Phase 1 trial completes dosing of first cohort with safety readout",
      "source": "https://lifespan.io/first-human-cellular-reprogramming-trial-cleared-by-the-fda/",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -9,
      "source_id": null,
      "confidence": 0.7,
      "expected_date": "2027-03-17",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2027-12-31",
        "from": "2026-06-01"
      },
      "measurement_criterion": "Life Biosciences or co-sponsor publishes Phase 1 first-cohort completion or interim safety data for partial cellular reprogramming therapy ER-100 (NAION/optic neuropathies) via press release, ClinicalTrials.gov, or peer-reviewed paper"
    },
    {
      "kind": "prereq",
      "label": "Colossal's $10B valuation is massively undervalued",
      "status": "pending",
      "weight": 0.5,
      "ordinal": -8,
      "source_id": "245_003",
      "expected_date": "2027-12-08",
      "observed_date": null
    },
    {
      "kind": "llm_pre_event",
      "label": "Second independent FDA-cleared partial-reprogramming or epigenetic-rejuvenation human trial enters dosing",
      "source": "https://longevity.technology/news/fda-clears-first-human-trial-of-epigenetic-reprogramming-therapy/",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -7,
      "source_id": null,
      "confidence": 0.6,
      "expected_date": "2028-07-01",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2029-12-31",
        "from": "2027-01-01"
      },
      "measurement_criterion": "FDA grants IND clearance and dosing begins for a second distinct partial-reprogramming or epigenetic-age-reversal therapy from a different sponsor (e.g., Altos Labs, NewLimit, Retro Biosciences); confirmed by FDA, ClinicalTrials.gov, or sponsor PR"
    },
    {
      "kind": "prereq",
      "label": "Big pharma companies will transition into longevity business in next 3 years.",
      "status": "pending",
      "weight": 0.5,
      "ordinal": -6,
      "source_id": "235_029",
      "expected_date": "2028-09-09",
      "observed_date": null
    },
    {
      "kind": "llm_pre_event",
      "label": "Peer-reviewed human study demonstrates statistically significant biological-age rev
... (truncated)